In a study involving rats with AD-like symptoms, it was found that emodin, an AQ, lowered plaque Aβ levels and tau hyperphosphorylation by reducing BACE1 levels in the hippocampi and enhancing the activity of protein phosphatase 2A (PP2A). Here, BACE1 is linked to Alzheimer disease.